Stenvall joins the company after a tenure leading the diabetes and cardiovascular-disease franchises at Sanofi. Her industry background also includes significant roles at AstraZeneca and Pfizer, positioning her to steer the firm's vaccine portfolio through its next growth cycle.

Paul Chaplin, the longtime chief executive, confirmed in March his intention to step down by year-end, citing personal reasons. The board’s selection of Stenvall signals a focus on continuity and experienced leadership as the company navigates the competitive landscape of international vaccine production.